Literature DB >> 2450260

Antihypertensive effect of canrenone in a model where endogenous ouabain-like factors are present.

M de Mendonça1, M L Grichois, M G Pernollet, I Wauquier, B Trouillet-Thormann, P Meyer, M A Devynck, R Garay.   

Abstract

The effect of canrenone, an antialdosterone and partial ouabain-agonist drug, was studied in rats that developed volume expansion and hypertension after renal mass reduction and excess Na+ intake (RRM-salt). The RRM-salt was characterized by: (1) increased endogenous "digitalis-like" compounds in plasma [cross reactivity with digoxin-antibodies (57.5 +/- 5.0 vs. 42.1 +/- 3.8 pg/ml, p less than 0.02); inhibition of kidney Na+, K+-ATPase activity (135 +/- 5 vs. 154 +/- 5 mumol/mg/h, p less than 0.01); and inhibition of Na+ extrusion from normal erythrocytes (5.96 +/- 0.40 vs. 7.68 +/- 0.34 mmol/L cells/h, p less than 0.01)]; (2) reduced Na+, K+-pump activity (7.34 +/- 0.29 vs. 10.88 +/- 0.41 mmol/L cells/h, p less than 0.001) and increased Na+ content (4.66 +/- .08 vs. 4.16 +/- 0.11 mmol/L cells, p less than 0.01) in erythrocytes; and (3) low plasma renin activity (2.1 +/- 0.9 vs. 12.6 +/- 1.6 ng/ml/h). Ninety minutes after the administration to RRM-salt of a single oral dose of 60 mg/kg of canrenone, the systolic blood pressure decreased by 36 +/- 4 mm Hg (mean +/- SEM). Chronic canrenone administration (60 mg/kg/day) resulted in a marked antihypertensive effect associated to a correction of volume expansion, a decrease in endogenous "digitalis-like" compounds, and a partial recovery of Na+, K+-pump activity and Na+ content in erythrocytes. Our results suggest that the antihypertensive effect in RRM-salt rats results, at least in part, from antagonism with endogenous "digitalis-like" compounds.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2450260     DOI: 10.1097/00005344-198801000-00012

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  7 in total

Review 1.  Endogenous digitalis: pathophysiologic roles and therapeutic applications.

Authors:  Alexei Y Bagrov; Joseph I Shapiro
Journal:  Nat Clin Pract Nephrol       Date:  2008-06-10

Review 2.  Endogenous cardiotonic steroids: physiology, pharmacology, and novel therapeutic targets.

Authors:  Alexei Y Bagrov; Joseph I Shapiro; Olga V Fedorova
Journal:  Pharmacol Rev       Date:  2009-03       Impact factor: 25.468

Review 3.  Endogenous cardiotonic steroids in kidney failure: a review and an hypothesis.

Authors:  John M Hamlyn; Paolo Manunta
Journal:  Adv Chronic Kidney Dis       Date:  2015-05       Impact factor: 3.620

Review 4.  Endogenous cardiotonic steroids and salt-sensitive hypertension.

Authors:  Olga V Fedorova; Joseph I Shapiro; Alexei Y Bagrov
Journal:  Biochim Biophys Acta       Date:  2010-03-27

Review 5.  The Pressure of Aging.

Authors:  Majd AlGhatrif; Mingyi Wang; Olga V Fedorova; Alexei Y Bagrov; Edward G Lakatta
Journal:  Med Clin North Am       Date:  2017-01       Impact factor: 5.456

6.  Marinobufagenin-induced vascular fibrosis is a likely target for mineralocorticoid antagonists.

Authors:  Olga V Fedorova; Igor V Emelianov; Konstantin A Bagrov; Yulia N Grigorova; Wen Wei; Ondrej Juhasz; Elena V Frolova; Courtney A Marshall; Edward G Lakatta; Alexandra O Konradi; Alexei Y Bagrov
Journal:  J Hypertens       Date:  2015-08       Impact factor: 4.844

7.  Canrenone Restores Vasorelaxation Impaired by Marinobufagenin in Human Preeclampsia.

Authors:  Natalia I Agalakova; Yulia N Grigorova; Ivan A Ershov; Vitaly A Reznik; Elena V Mikhailova; Olga V Nadei; Leticia Samuilovskaya; Larisa A Romanova; C David Adair; Irina V Romanova; Alexei Y Bagrov
Journal:  Int J Mol Sci       Date:  2022-03-19       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.